Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

This study is exploring whether patients with chronic myeloid leukemia (CML) — a type of blood cancer — who have been in very deep remission for a long time can safely stop taking their targeted therapy (TKI) medication without the cancer returning. This is sometimes called "treatment-free remission." **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of CML (Philadelphia chromosome positive) - You have been taking a TKI medication for more than 3 years - Your cancer has been undetectable (MR4.5 level remission) for at least 24 months, confirmed by 3 or more tests - Your blood counts and organ function are within healthy ranges - You are in good general health (able to carry out normal daily activities) **You may NOT be eligible if...** - You have had or are planning a stem cell transplant from a donor - You have HIV or active liver disease - You have had another active cancer - You missed more than 2 weeks of TKI treatment in the past 6 months - You received another experimental treatment in the last 2 years Talk to your doctor to see if this trial is right for you.